文献速递血液净化与透析水电解质与酸碱

Tenapanor联合磷结合剂治疗难治性高磷血症的随机研究

Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia.
PubMed 文献 · Kidney Int Rep · 2023-08-13

本研究在169例日本血液透析患者中评估Tenapanor联合磷结合剂(PBs)的疗效与安全性。患者血清磷≥6.1且<10.0 mg/dl,随机接受安慰剂+PBs(n=85)或Tenapanor+PBs(n=84)治疗8周。结果显示Tenapanor组血清磷较基线下降-2.00 mg/dl,安慰剂组下降-0.24 mg/dl,组间差异显著(-1.76 mg/dl,P<0.0001)。腹泻是最常见不良事件,两组发生率分别为63.1%和14.1%,均为轻中度。

要点

  • Tenapanor联合PBs可显著降低PBs控制不佳的透析患者血清磷水平。
  • Tenapanor组血清磷降幅达-2.00 mg/dl,安慰剂组仅-0.24 mg/dl。
  • 腹泻发生率Tenapanor组63.1%,安慰剂组14.1%,均为轻中度。

核心结论

  • Tenapanor联合PBs改善了单用PBs无法控制的血清磷水平,且未发现新的安全性问题。

研究设计与样本

  • 随机对照研究,纳入169例日本血液透析高磷血症患者,血清磷≥6.1且<10.0 mg/dl,随机分为安慰剂+PBs组(n=85)和Tenapanor+PBs组(n=84),治疗8周。

主要发现

  • 血清磷从基线至第8周的最小二乘均值变化:安慰剂组-0.24 mg/dl vs Tenapanor组-2.00 mg/dl,组间差异-1.76 mg/dl(P<0.0001)。
  • 腹泻作为治疗中出现的不良事件(TEAE)发生率:安慰剂组14.1% vs Tenapanor组63.1%,所有腹泻事件均为轻或中度。

临床怎么用

  • 对于单用PBs控制不佳的血液透析高磷血症患者,可考虑加用Tenapanor以进一步降低血清磷水平。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Serum phosphorus management is important for patients with chronic kidney disease on dialysis to reduce the risk of hyperparathyroidism and ectopic vascular calcification. Phosphate binders (PBs) control serum phosphorus levels; however, some patients do not achieve adequate control with existing PBs. The similar mechanisms of action of each PB may limit their ability to lower serum phosphorus levels. Therefore, drugs with novel mechanisms of action that can be added to existing PBs to further lower serum phosphorus levels are desired. Tenapanor, a novel selective inhibitor of intestinal sodium/hydrogen exchanger 3 transporters, decreases passive phosphate absorption in the intestine, thereby decreasing serum phosphorus levels. METHODS: This study evaluated the efficacy and safety of tenapanor treatment with up-titration when added to PBs among Japanese hemodialysis patients with hyperphosphatemia poorly controlled by PBs alone. In total, 169 patients taking PBs whose serum phosphorus level was ≥6.1 and <10.0 mg/dl initiated the 8-week treatment (placebo + PB, n = 85; tenapanor + PB, n = 84). RESULTS: The least squares mean change from baseline to week 8 in serum phosphorus level was -0.24 and -2.00 mg/dl in the placebo and tenapanor groups, respectively, with a statistically significant difference between groups (-1.76 mg/dl; P < 0.0001). Diarrhea as a treatment-emergent adverse event (TEAE) occurred in 14.1% and 63.1% of patients in the placebo and tenapanor groups, respectively. All diarrhea events were mild or moderate. CONCLUSION: Tenapanor added to PBs improved serum phosphorus levels that could not previously be controlled by PBs alone, and no new safety concerns were raised.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Nitta K, Itoyama S, Ikejiri K, et al. Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia. Kidney Int Rep. 2023. PMID: 38025211. doi:10.1016/j.ekir.2023.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。